These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 9537221

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response.
    Page RL, Connolly SJ, Wilkinson WE, Marcello SR, Schnell DJ, Pritchett EL, Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators.
    Am Heart J; 2002 Apr; 143(4):643-9. PubMed ID: 11923801
    [Abstract] [Full Text] [Related]

  • 25. Azimilide, a novel oral class III antiarrhythmic for both supraventricular and ventricular arrhythmias.
    VerNooy RA, Mangrum JM.
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Feb; 5(1):75-84. PubMed ID: 15720225
    [Abstract] [Full Text] [Related]

  • 26. Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide.
    Page RL, Tilsch TW, Connolly SJ, Schnell DJ, Marcello SR, Wilkinson WE, Pritchett EL, Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators.
    Circulation; 2003 Mar 04; 107(8):1141-5. PubMed ID: 12615792
    [Abstract] [Full Text] [Related]

  • 27. Role of antiarrhythmic agents after myocardial infarction with special reference to the EMIAT and CAMIAT trials of amiodarone. European Myocardial Infarct Amiodarone Trial. Canadian Amiodarone Myocardial Infarction Trial.
    Jafri SM, Borzak S, Goldberger J, Gheorghiade M.
    Prog Cardiovasc Dis; 1998 Mar 04; 41(1):65-70. PubMed ID: 9717860
    [Abstract] [Full Text] [Related]

  • 28. Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm.
    Pritchett EL, Kowey P, Connolly S, Page RL, Kerr C, Wilkinson WE, A-COMET-I Investigators.
    Am Heart J; 2006 May 04; 151(5):1043-9. PubMed ID: 16644334
    [Abstract] [Full Text] [Related]

  • 29. The effect of isoproterenol on the class III effect of azimilide in humans.
    Dorian P, Dunnmon P, Elstun L, Newman D.
    J Cardiovasc Pharmacol Ther; 2002 Oct 04; 7(4):211-7. PubMed ID: 12490966
    [Abstract] [Full Text] [Related]

  • 30. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties.
    Nattel S, Liu L, St-Georges D.
    Cardiovasc Res; 1998 Mar 04; 37(3):627-35. PubMed ID: 9659446
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial.
    Lombardi F, Borggrefe M, Ruzyllo W, Lüderitz B, A-COMET-II Investigators.
    Eur Heart J; 2006 Sep 04; 27(18):2224-31. PubMed ID: 16935870
    [Abstract] [Full Text] [Related]

  • 33. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators.
    Singer I, Al-Khalidi H, Niazi I, Tchou P, Simmons T, Henthorn R, Holroyde M, Brum J.
    J Am Coll Cardiol; 2004 Jan 07; 43(1):39-43. PubMed ID: 14715180
    [Abstract] [Full Text] [Related]

  • 34. Amiodarone and "primary" prevention of sudden death: critical review of a decade of clinical trials.
    Farré J, Romero J, Rubio JM, Ayala R, Castro-Dorticós J.
    Am J Cardiol; 1999 Mar 11; 83(5B):55D-63D. PubMed ID: 10089841
    [Abstract] [Full Text] [Related]

  • 35. Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation.
    Pritchett EL, Schulte MC, Schnell D, Marcello SR, Wilkinson WE, Page RL, Connolly SJ, Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators.
    J Clin Pharmacol; 2002 Apr 11; 42(4):388-94. PubMed ID: 11936563
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug.
    Black SC, Butterfield JL, Lucchesi BR.
    J Cardiovasc Pharmacol; 1993 Dec 11; 22(6):810-8. PubMed ID: 7509898
    [Abstract] [Full Text] [Related]

  • 39. [Azimilide: Search for an effective and well-tolerated anti-arrhythmia agent].
    Z Kardiol; 1999 Oct 11; 88(10 Suppl):1-2. PubMed ID: 10586493
    [No Abstract] [Full Text] [Related]

  • 40. Lessons from antiarrhythmic trials involving class III antiarrhythmic drugs.
    Yap YG, Camm AJ.
    Am J Cardiol; 1999 Nov 04; 84(9A):83R-89R. PubMed ID: 10568665
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.